CommercialCoverageMedium impact
Pharmacy Program Quarterly Update Changes Effective April 1, 2025 – Part 2
BCBS Texas·TX · Pharmacy, Endocrinology, Oncology +4 more·Pharmacy
Effective date
Apr 1, 2025
We identified it
Jan 12, 2026
Summary
Blue Cross and Blue Shield of Texas is adding 40+ new medications to multiple drug formularies effective April 1, 2025, including new specialty drugs for autoimmune disorders, atopic dermatitis, cancer, diabetes management (insulin pump supplies/devices), and other conditions. This is Part 2 of the quarterly pharmacy update and does not require member notification. Billing teams must ensure claims for these newly covered drugs are processed correctly without prior authorization denials for coverage reasons.
Action Required
By March 31, 2025: Billing team must update pharmacy billing system to recognize the following newly covered drugs on BCBSTX formularies: ADALIMUMAB-ADAZ, EBGLYSS, ERYTHROMYCIN DR, FEMLYV, fluoxetine hcl, ILET insulin pump devices and supplies (multiple kits), LAZCLUZE, LIVMARLI, NEMLUVIO, NYVEPRIA, OXYCODONE HYDROCHLORIDE, ROXYBOND, SOFDRA, TWIIST insulin pump supplies/kits, VIGAFYDE, VORANIGO, NITAZOXANIDE, and AIRSUPRA. Verify these drugs are coded correctly in the system for each applicable plan tier (Balanced, Performance, Performance Annual, Performance Select, Basic, Enhanced, and Multi-Tier variants). Update prior authorization protocols to ensure these drugs are not denied for lack of formulary coverage. Note: Some drugs (AIRSUPRA, APRETUDE, DUVYZAT) became effective on 2/1/2025 and should already be processed. Train billing and prior auth staff on the new drug additions to prevent claim rejections. Failure to update the system may result in claims being denied for non-covered drugs when they are now covered.